Missing doesn’t raise money. He puts shares to his vulture investor who then turns around and sells the shares back into the market for a quick, easy profit (at the expense of shareholders). You don’t have to be a financial wizard to do that.
Actually raising money from sophisticated institutional biotech investors is hard. The bar is high when it comes to due diligence. Deep scrutiny by sophisticated investors is not something Missling welcomes.
News 
Market Data 
Discover 
